Scientific Interest(s):
Dr. Sara Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. She is particularly interested in the development and testing of new targeted therapies for the treatment of breast cancer.
Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.
Selected Cancer-Related Publications:
Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 1;113(9):2385-97.
Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A. Role of Age and Health in Treatment Recommendations for Older Adults With Breast Cancer: The Perspective of Oncologists and Primary Care Providers. J Clin Oncol. 2008 Oct 27. [Epub ahead of print].
Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008 Sep 15;181(6):4131-40.
Ancheta RG, Lewin H, Said J, Hurvitz SA. Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer. J Clin Oncol. 2008 Jan 10;26(2):326-8.
Konecny G, Hurvitz SA. Rationale and clinical data for combined inhibition of HER2 and vascular endothelial growth factor receptor pathways in breast cancer. Biological Therapy of Breast Cancer 8(4), November 2007.